Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Personalized vaccine targets key driver mutations and induces antitumor immunity in fully resected high-risk clear cell renal cell carcinoma.

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

A new personalized cancer vaccine has shown encouraging results in preventing the return of kidney cancer after surgery.

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Immunotherapy revolutionises cancer treatment by harnessing the immune system, offering targeted therapy with fewer side ...

A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

"We want to improve post-surgery treatment options that reduce ... published Feb. 5 in the journal Nature. The new trial focused on patients with advanced, stage 3 or 4 clear cell renal [kidney] cell ...